新的治疗点分子用于胃和胃食道结癌
1Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-sayama, 589-8511, Japan. kawakami_h@med.kindai.ac.jp.
针对胃癌的向治疗因患者选择问题而面临挑战. 新的战略侧重于精确的药物输送标记,扩大治疗选择超出传统的瘤原因驱动因素.
科学领域:
- 在瘤学瘤学.
- 分子向疗法分子向疗法
- 胃肠道癌症 胃肠道癌症
背景情况:
- 对受体氨酸激酶 (RTK) 的分子向疗法在胃和胃食道结 (G/GEJ) 癌症中表现出有限的成功.
- 挑战包括不适当的测试选择,遗传异常和内异质性,阻碍了对RTK向药物的患者鉴定.
- 针对RTK的免疫组织化学在患者选择中基本上没有成功,在小患者队列中检测RTK基因放大很难.
研究的目的:
- 审查G/GEJ癌症分子向治疗的局限性和进展.
- 突出患者选择和药物开发中不断变化的策略,用于G/GEJ癌症.
- 讨论针对非驱动分子进行精确的药物输送的潜力.
主要方法:
- 对临床试验数据和关于针对性治疗的科学文献的综述 G/GEJ癌症.
- 分析特定向药物的疗效,包括抗体和抗体与药物联合体 (ADCs).
- 评估用于识别可向生物标志物的诊断方法,如FGFR2b和CLDN18.2.2.
主要成果:
- FGFR2放大与预后不佳有关,而FGFR2b免疫组织化学有效地识别了FGFR2依赖性瘤,支持了bemarituzumab试验.
- 抗体-药物联体 (ADC) 和双特异性抗体正在解决EGFR和MET向疗法的挑战.
- 佐尔贝图西马布在CLDN18.2-阳性G/GEJ癌症患者中显示出生存益处,针对CLDN18.2的ADC也在调查中.
- 针对DKK1,TROP2和CEACAM5等非驱动分子正在早期试验中进行探索.
结论:
- 焦点正在从瘤驱动器目标转移到精确药物输送的标记物,可能增加G/GEJ癌症的治疗选择.
- 基于抗体的疗法和诊断试验的进步对于改善G/GEJ癌症患者的治疗结果至关重要.
- 准CLDN18.2和探索新型标记物代表了未来G/GEJ癌症治疗策略的有希望的途径.
更多相关视频
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Mitogens and the Cell Cycle
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
